We have recently received the approval of the NMPA for the issuance of the Drug Registration Approval, and the marketing approval of pitavastatin calcium tablets (2 mg), a new generation of statins for lipid regulation, is regarded as passing the consistency evaluation.

Pitavastatin calcium tablets are used for the treatment of hypercholesterolemia and familial hypercholesterolemia, with the characteristics of minimal dose, safer combination, and less impact on renal function, and are preferred for patients with type 2 diabetes combined with dyslipidemia.

The approval of Aoding® (pitavastatin calcium tablets) complements and strengthens our product line in the cardiovascular field, while providing patients in China with a more secure, high-quality, potent statin lipid regulator.